Alpha Cognition Inc. to Present New Clinical Data on ZUNVEYL® and Cholinesterase Inhibitors at ASCP Annual Meeting

Reuters

Oct 06, 2025

<a href="https://laohu8.com/S/ACOGD">Alpha Cognition Inc.</a> to Present New Clinical Data on ZUNVEYL® and Cholinesterase Inhibitors at ASCP Annual Meeting

Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company focused on therapies for neurodegenerative diseases, has announced that it will present new clinical insights regarding cholinesterase inhibitors and its product ZUNVEYL® (Benzgalantamine) at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, scheduled for October 23-25, 2025. The company will showcase data through several posters, including topics such as acetylcholinesterase inhibitors and psychotropic medication use in Alzheimer's disease and related dementias $(ADRD)$, persistence of therapy in ADRD, and evidence-based approaches to switching acetylcholinesterase inhibitors in Alzheimer's disease. The results are slated to be presented at the upcoming conference and have not yet been disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006913298) on October 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2573724056"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573724056\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573724056?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573724056","market":"nz","top_or_hot":-1,"title":"Alpha Cognition Inc. to Present New Clinical Data on ZUNVEYL® and Cholinesterase Inhibitors at ASCP Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ACOGD\">Alpha Cognition Inc.</a> to Present New Clinical Data on ZUNVEYL® and Cholinesterase Inhibitors at ASCP Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACOGF\">Alpha Cognition Inc.</a> (Nasdaq: ACOG), a commercial-stage biopharmaceutical company focused on therapies for neurodegenerative diseases, has announced that it will present new clinical insights regarding cholinesterase inhibitors and its product ZUNVEYL® (Benzgalantamine) at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, scheduled for October 23-25, 2025. The company will showcase data through several posters, including topics such as acetylcholinesterase inhibitors and psychotropic medication use in Alzheimer's disease and related dementias <a href=\"https://laohu8.com/S/ADRD\">$(ADRD)$</a>, persistence of therapy in ADRD, and evidence-based approaches to switching acetylcholinesterase inhibitors in Alzheimer's disease. The results are slated to be presented at the upcoming conference and have not yet been disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ACOG\">Alpha Cognition</a> Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006913298) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alpha Cognition Inc. to Present New Clinical Data on ZUNVEYL® and Cholinesterase Inhibitors at ASCP Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlpha Cognition Inc. to Present New Clinical Data on ZUNVEYL® and Cholinesterase Inhibitors at ASCP Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-06 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ACOGD\">Alpha Cognition Inc.</a> to Present New Clinical Data on ZUNVEYL® and Cholinesterase Inhibitors at ASCP Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACOGF\">Alpha Cognition Inc.</a> (Nasdaq: ACOG), a commercial-stage biopharmaceutical company focused on therapies for neurodegenerative diseases, has announced that it will present new clinical insights regarding cholinesterase inhibitors and its product ZUNVEYL® (Benzgalantamine) at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, scheduled for October 23-25, 2025. The company will showcase data through several posters, including topics such as acetylcholinesterase inhibitors and psychotropic medication use in Alzheimer's disease and related dementias <a href=\"https://laohu8.com/S/ADRD\">$(ADRD)$</a>, persistence of therapy in ADRD, and evidence-based approaches to switching acetylcholinesterase inhibitors in Alzheimer's disease. The results are slated to be presented at the upcoming conference and have not yet been disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ACOG\">Alpha Cognition</a> Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006913298) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL473yR9:1","article_id":"2573724056","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573724056","pubTimestamp":1759753827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire  on October 06, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ACOG":"ALPHA COGNITION INC"},"translate_title":"Alpha Cognition Inc.将展示ZUNVEYL的新临床数据®和胆碱酯酶抑制剂在ASCP年会上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACOG":0.9},"content_text":"Alpha Cognition Inc. to Present New Clinical Data on ZUNVEYL® and Cholinesterase Inhibitors at ASCP Annual Meeting\n    \n\nAlpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company focused on therapies for neurodegenerative diseases, has announced that it will present new clinical insights regarding cholinesterase inhibitors and its product ZUNVEYL® (Benzgalantamine) at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, scheduled for October 23-25, 2025. The company will showcase data through several posters, including topics such as acetylcholinesterase inhibitors and psychotropic medication use in Alzheimer's disease and related dementias $(ADRD)$, persistence of therapy in ADRD, and evidence-based approaches to switching acetylcholinesterase inhibitors in Alzheimer's disease. The results are slated to be presented at the upcoming conference and have not yet been disclosed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006913298) on October 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}